{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:34:05Z","timestamp":1789065245121,"version":"build-2803163510"},"reference-count":332,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Verdun Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>\u03b2-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 76 studies (4 in vitro and 2 animal experiments, 1 pharmacokinetic simulation study, 37 pharmacokinetic studies on patients with end-stage kidney disease, and 32 case reports or case series) met inclusion criteria. Toxicokinetic or pharmacokinetic data were available on 334 patients (including 73 for atenolol, 54 for propranolol, and 17 for sotalol). For intermittent hemodialysis, atenolol, nadolol, practolol, and sotalol were assessed as dialyzable; acebutolol, bisoprolol, and metipranolol were assessed as moderately dialyzable; metoprolol and talinolol were considered slightly dialyzable; and betaxolol, carvedilol, labetalol, mepindolol, propranolol, and timolol were considered not dialyzable. Data were available for clinical analysis on 37 BAA poisoned patients (including 9 patients for atenolol, 9 for propranolol, and 9 for sotalol), and no reliable comparison between the ECTR cohort and historical controls treated with standard care alone could be performed. The EXTRIP workgroup recommends against using ECTR for patients severely poisoned with propranolol (strong recommendation, very low quality evidence). The workgroup offered no recommendation for ECTR in patients severely poisoned with atenolol or sotalol because of apparent balance of risks and benefits, except for impaired kidney function in which ECTR is suggested (weak recommendation, very low quality of evidence). Indications for ECTR in patients with impaired kidney function include refractory bradycardia and hypotension for atenolol or sotalol poisoning, and recurrent torsade de pointes for sotalol. Although other BAAs were considered dialyzable, clinical data were too limited to develop recommendations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>BAAs have different properties affecting their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13054-021-03585-7","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T14:03:08Z","timestamp":1623333788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6869-7663","authenticated-orcid":false,"given":"Jos\u00e9e","family":"Bouchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greene","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Lavergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ghannoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EXTRIP workgroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greene","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Lavergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ghannoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badria","family":"Alhatali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Anseeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Berling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E","family":"Bunchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane P","family":"Calello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tais","family":"Galvao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hassanian-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte CG","family":"Hoegberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba","family":"Kallab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Kebede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne M","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Megarbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitha","family":"Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"3585_CR1","doi-asserted-by":"crossref","unstructured":"Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020:1\u201341.","DOI":"10.1080\/15563650.2020.1752918"},{"issue":"3","key":"3585_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.ackd.2011.01.008","volume":"18","author":"M Ghannoum","year":"2011","unstructured":"Ghannoum M, Nolin TD, Lavergne V, Hoffman RS. Blood purification in toxicology: nephrology\u2019s ugly duckling. Adv Chronic Kidney Dis. 2011;18(3):160\u20136.","journal-title":"Adv Chronic Kidney Dis"},{"key":"3585_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/15563650.2012.683436","volume":"50","author":"V Lavergne","year":"2012","unstructured":"Lavergne V, Nolin TD, Hoffman RS, Robert D, Gosselin S, Goldfarb DS, et al. The EXTRIP (Extracorporeal Treatments In Poisoning) workgroup: Guideline methodology. Clin Toxicol. 2012;50:403\u201313.","journal-title":"Clin Toxicol"},{"issue":"10","key":"3585_CR4","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1681\/ASN.2020050564","volume":"31","author":"I Berling","year":"2020","unstructured":"Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, et al. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. J Am Soc Nephrol. 2020;31(10):2475\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"3585_CR5","doi-asserted-by":"crossref","unstructured":"Wong A, Hoffman RS, Walsh SJ, Roberts DM, Gosselin S, Bunchman TE, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2021:1\u201331.","DOI":"10.1080\/15563650.2020.1870123"},{"key":"3585_CR6","unstructured":"The 50 most commonly prescribed drugs in America and their average price 2020 [Available from: https:\/\/www.drugreport.com\/50-commonly-prescribed-drugs-in-america\/."},{"key":"3585_CR7","unstructured":"WHO. WHO Model Lists of Essential Medicines 2019 [Available from: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"issue":"1","key":"3585_CR8","first-page":"27","volume":"7","author":"F Ducret","year":"1978","unstructured":"Ducret F, Zech P, Perrot D, Moskovtchenko JF, Traeger J. Deliberate self-overdose with propranolol. Changes in serum levels. Nouv Presse Med. 1978;7(1):27\u20138.","journal-title":"Nouv Presse Med"},{"issue":"9","key":"3585_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/15563650.2016.1209768","volume":"54","author":"GK Isbister","year":"2016","unstructured":"Isbister GK, Ang K, Gorman K, Cooper J, Mostafa A, Roberts MS. Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. Clin Toxicol. 2016;54(9):881\u20135.","journal-title":"Clin Toxicol"},{"issue":"6","key":"3585_CR10","first-page":"528","volume":"56","author":"J Grass","year":"2018","unstructured":"Grass J, Steinwall J, Lindeman E. Prolonged elimination after massive overdose of metoprolol and amlodipine in a patient treated with extracorporeal life support (ECLS). Clin Toxicol (Phila). 2018;56(6):528\u20139.","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"3585_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1081\/CLT-100102018","volume":"38","author":"CP Snook","year":"2000","unstructured":"Snook CP, Sigvaldason K, Kristinsson J. Severe atenolol and diltiazem overdose. J Toxicol Clin Toxicol. 2000;38(6):661\u20135.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"2","key":"3585_CR12","first-page":"268","volume":"29","author":"PJ Neuvonen","year":"1981","unstructured":"Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. Prolonged Q-T interval and severe tachyarrhythmias: common features in patients with sotalol overdosage. Clin Pharmacol Ther. 1981;29(2):268.","journal-title":"Clin Pharmacol Ther"},{"issue":"2 Pt 1","key":"3585_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0002-8703(91)90735-Z","volume":"121","author":"SN Singh","year":"1991","unstructured":"Singh SN, Lazin A, Cohen A, Johnson M, Fletcher RD. Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy. Am Heart J. 1991;121(2 Pt 1):601\u20132.","journal-title":"Am Heart J"},{"issue":"7\u20138","key":"3585_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/106002809703100709","volume":"31","author":"CG Gustavsson","year":"1997","unstructured":"Gustavsson CG, Vinge E, Norlander BO, Pantev E. Pharmacokinetic evaluation of a case of massive sotalol intoxication. Ann Pharmacother. 1997;31(7\u20138):856\u20139.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3585_CR15","first-page":"47","volume":"33","author":"R Miethe","year":"1996","unstructured":"Miethe R, Habel U, Schuster HP. 8 g sotalol self-poisoning treated with hemoperfusion\/hemodialysis. Intensivmedizin und Notfallmedizin. 1996;33(1):47\u201351.","journal-title":"Intensivmedizin und Notfallmedizin"},{"issue":"1","key":"3585_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/00000542-199507000-00025","volume":"83","author":"LGR DeLima","year":"1995","unstructured":"DeLima LGR, Kharasch ED, Butler S. Successful pharmacologic treatment of massive atenolol overdose: sequential hemodynamics and plasma atenolol concentrations. Anesthesiology. 1995;83(1):204\u20137.","journal-title":"Anesthesiology"},{"issue":"5","key":"3585_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/096032718600500510","volume":"5","author":"S Freestone","year":"1986","unstructured":"Freestone S, Thomas HM, Bhamra RK, Dyson EH. Severe atenolol poisoning: treatment with prenalterol. Hum Toxicol. 1986;5(5):343\u20135.","journal-title":"Hum Toxicol"},{"issue":"3","key":"3585_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF03161225","volume":"5","author":"C Page","year":"2009","unstructured":"Page C, Hacket LP, Isbister GK. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol. 2009;5(3):139\u201343.","journal-title":"J Med Toxicol"},{"issue":"5 Pt 1","key":"3585_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/cpt1977225part1557","volume":"22","author":"PJ Meffin","year":"1977","unstructured":"Meffin PJ, Winkle RA, Peters FA, Harrison DC. Acebutolol disposition after intravenous administration. Clin Pharmacol Ther. 1977;22(5 Pt 1):557\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3585_CR20","doi-asserted-by":"publisher","first-page":"446P","DOI":"10.1111\/j.1365-2125.1978.tb04617.x","volume":"6","author":"HE Barber","year":"1978","unstructured":"Barber HE, Hawksworth GM, Kitteringham NR, Petersen J, Petrie JC, Swann JM. Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings]. Br J Clin Pharmacol. 1978;6(5):446P-P447.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3585_CR21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1080\/15563650.2020.1834219","volume":"58","author":"DD Gummin","year":"2020","unstructured":"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brooks DE, Dibert KW, et al. 2019 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila). 2020;58(12):1360\u2013541.","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"3585_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1081\/CLT-100100932","volume":"38","author":"JN Love","year":"2000","unstructured":"Love JN, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38(3):275\u201381.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"10","key":"3585_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3109\/15563650.2010.534483","volume":"48","author":"B Megarbane","year":"2010","unstructured":"Megarbane B, Deye N, Malissin I, Baud FJ. Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning. Clin Toxicol. 2010;48(10):974\u20138.","journal-title":"Clin Toxicol"},{"key":"3585_CR24","first-page":"350","volume":"40","author":"M Hermanns-Clausen","year":"2002","unstructured":"Hermanns-Clausen M, Desel H. Sotalol overdose: how dangerous is it? Clin Toxicol. 2002;40:350.","journal-title":"Clin Toxicol"},{"issue":"3","key":"3585_CR25","first-page":"207","volume":"2","author":"D Elkharrat","year":"1982","unstructured":"Elkharrat D, Bismuth C. Acute intoxication by beta-blocking agents: No mortality in 40 cases Blocking of beta-adrenoreceptors may be an autolimited phenomenon. Int J Clin Pharmacol Res. 1982;2(3):207\u201310.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"6","key":"3585_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0736-4679(94)90487-1","volume":"12","author":"JN Love","year":"1994","unstructured":"Love JN. Beta blocker toxicity after overdose: when do symptoms develop in adults? J Emerg Med. 1994;12(6):799\u2013802.","journal-title":"J Emerg Med"},{"issue":"3","key":"3585_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/15563659609013789","volume":"34","author":"DM Reith","year":"1996","unstructured":"Reith DM, Dawson AH, Epid D, Whyte IM, Buckley NA, Sayer GP. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34(3):273\u20138.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"3585_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1081\/CLT-62475","volume":"43","author":"P Wax","year":"2005","unstructured":"Wax P, Erdman A, Chyka P, Keyes D, Caravati EM, Booze L, et al. beta-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005;43(3):131\u201346.","journal-title":"Clin Toxicol"},{"issue":"12","key":"3585_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0196-0644(84)80337-6","volume":"13","author":"RS Weinstein","year":"1984","unstructured":"Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984;13(12):1123\u201331.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"3585_CR30","first-page":"253","volume":"32","author":"P Auzepy","year":"1983","unstructured":"Auzepy P, Boukara N, Richard C, Giudicelli JF. Acute poisoning caused by beta blockers in the adult. Apropos of 7 cases. Ann Cardiol Angeiol (Paris). 1983;32(4):253\u20138.","journal-title":"Ann Cardiol Angeiol (Paris)."},{"issue":"1","key":"3585_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/archinte.1987.00370010043011","volume":"147","author":"FM Gengo","year":"1987","unstructured":"Gengo FM, Huntoon L, McHugh WB. Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Arch Intern Med. 1987;147(1):39\u201343.","journal-title":"Arch Intern Med."},{"issue":"2","key":"3585_CR32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bcpt.13231","volume":"125","author":"M Lauterbach","year":"2019","unstructured":"Lauterbach M. Clinical toxicology of beta-blocker overdose in adults. Basic Clin Pharmacol Toxicol. 2019;125(2):178\u201386.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"3585_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006565-199908000-00007","volume":"15","author":"M Lifshitz","year":"1999","unstructured":"Lifshitz M, Zucker N, Zalzstein E. Acute dilated cardiomyopathy and central nervous system toxicity following propranolol intoxication. Pediatr Emerg Care. 1999;15(4):262\u20133.","journal-title":"Pediatr Emerg Care"},{"issue":"1","key":"3585_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0300-9572(98)00146-4","volume":"40","author":"G Cammu","year":"1999","unstructured":"Cammu G, Geelen P, Baetens P, De Vos J, Demeyer I. Two cases of torsades de pointes caused by sotalol therapy. Resuscitation. 1999;40(1):49\u201351.","journal-title":"Resuscitation"},{"issue":"7","key":"3585_CR35","first-page":"723","volume":"47","author":"AK Gupta","year":"2009","unstructured":"Gupta AK, Greller HA, Chan GM, Lee DC, Caraccio T, Mcguigan M, et al. Sotalol induced torsade de pointes and enhanced elimination with hemodialysis. Clin Toxicol. 2009;47(7):723.","journal-title":"Clin Toxicol"},{"issue":"18","key":"3585_CR36","first-page":"546","volume":"40","author":"G Oltmanns","year":"1985","unstructured":"Oltmanns G, Schwela H, Kulick B, Knappe J, Haustein KO, Schmidt H. Acute beta blocker poisoning. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete. 1985;40(18):546\u201351.","journal-title":"Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete"},{"issue":"6","key":"3585_CR37","first-page":"619","volume":"57","author":"S Vucinic","year":"2000","unstructured":"Vucinic S, Joksovic D, Jovanovic D, Vucinic Z, Todorovic V. Factors influencing the degree and outcome of acute beta-blockers poisoning. Vojnosanit Pregl. 2000;57(6):619\u201323.","journal-title":"Vojnosanit Pregl"},{"issue":"1","key":"3585_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00390-005-0517-9","volume":"42","author":"M Hermanns-Clausen","year":"2005","unstructured":"Hermanns-Clausen M, Sydow A, Desel H. Metoprolol overdoses - Clinical course in relation to ingested dose [German]. Intensivmedizin und Notfallmedizin. 2005;42(1):47\u201352.","journal-title":"Intensivmedizin und Notfallmedizin."},{"issue":"7","key":"3585_CR39","first-page":"746","volume":"47","author":"MB Forrester","year":"2009","unstructured":"Forrester MB. Pattern of adult carvedilol ingestions reported to poison control centers. Clin Toxicol. 2009;47(7):746\u20137.","journal-title":"Clin Toxicol"},{"issue":"6","key":"3585_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1191\/0960327106ht632oa","volume":"25","author":"JN Love","year":"2006","unstructured":"Love JN, Howell JM, Klein-Schwartz W, Litovitz TL. Lack of toxicity from pediatric beta-blocker exposures. Hum Exp Toxicol. 2006;25(6):341\u20136.","journal-title":"Hum Exp Toxicol"},{"issue":"6","key":"3585_CR41","first-page":"601","volume":"49","author":"P Dommer","year":"2011","unstructured":"Dommer P, Truitt CA, Brooks DE, LoVecchio F. Retrospective review of poison center data for unintentional beta-blocker and\/or calcium channel blocker ingestions. Clin Toxicol. 2011;49(6):601.","journal-title":"Clin Toxicol"},{"key":"3585_CR42","doi-asserted-by":"crossref","unstructured":"M'Rad A, Blel Y, Essafi F, Foudhaili N, Ben Slimen A, Brahmi N, et al. Prognostic value of plasma concentration of acebutolol in acute poisoning. Annals of Intensive Care Conference: French Intensive Care Society, International Congress Reanimation. 2016;6 (SUPPL. 1).","DOI":"10.1186\/s13613-016-0114-z"},{"issue":"3","key":"3585_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/0735-6757(94)90160-0","volume":"12","author":"JN Love","year":"1994","unstructured":"Love JN. Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med. 1994;12(3):356\u20137.","journal-title":"Am J Emerg Med"},{"key":"3585_CR44","doi-asserted-by":"crossref","unstructured":"Frishman W, Jacob H, Eisenberg E, Ribner H. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979;98 (6):798\u2013811.","DOI":"10.1016\/0002-8703(79)90480-0"},{"issue":"1","key":"3585_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0773.1979.tb02360.x","volume":"45","author":"PJ Neuvonen","year":"1979","unstructured":"Neuvonen PJ, Elonen E, Tarssanen L. Sotalol intoxication, two patients with concentration-effect relationships. Acta Pharmacol Toxicol (Copenh). 1979;45(1):52\u20137.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"13","key":"3585_CR46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/0002-9149(86)90692-2","volume":"57","author":"T Wang","year":"1986","unstructured":"Wang T, Bergstrand RH, Thompson KA, Siddoway LA, Duff HJ, Woosley RL, et al. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol. 1986;57(13):1160\u20135.","journal-title":"Am J Cardiol"},{"issue":"3","key":"3585_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000316050","volume":"116","author":"JC Somberg","year":"2010","unstructured":"Somberg JC, Preston RA, Ranade V, Molnar J. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology. 2010;116(3):219\u201325.","journal-title":"Cardiology"},{"issue":"3","key":"3585_CR48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/bcp.12201","volume":"77","author":"B Darpo","year":"2014","unstructured":"Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014;77(3):522\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1067\/mem.2002.129829","volume":"40","author":"JN Love","year":"2002","unstructured":"Love JN, Enlow B, Howell JM, Klein-Schwartz W, Litovitz TL. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40(6):603\u201310.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"3585_CR50","first-page":"292","volume":"130","author":"HG Eibs","year":"1982","unstructured":"Eibs HG, Oberdisse U, Brambach U. Intoxication by beta-blockers in children and adolescents (author\u2019s transl). Monatsschr Kinderheilkd. 1982;130(5):292\u20135.","journal-title":"Monatsschr Kinderheilkd"},{"issue":"12","key":"3585_CR51","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1080\/15563650.2019.1677022","volume":"57","author":"DD Gummin","year":"2019","unstructured":"Gummin DD, Mowry JB, Spyker DA, Brooks DE, Beuhler MC, Rivers LJ, et al. 2018 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila). 2019;57(12):1220\u2013413.","journal-title":"Clin Toxicol (Phila)"},{"key":"3585_CR52","first-page":"1","volume":"2018","author":"DD Gummin","year":"2017","unstructured":"Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterthaler KM, Banner W. Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol. 2017;2018:1\u2013203.","journal-title":"Clin Toxicol"},{"issue":"1","key":"3585_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s13181-012-0281-8","volume":"9","author":"NJ Johnson","year":"2013","unstructured":"Johnson NJ, Gaieski DF, Allen SR, Perrone J, DeRoos F. A review of emergency cardiopulmonary bypass for severe poisoning by cardiotoxic drugs. J Med Toxicol. 2013;9(1):54\u201360.","journal-title":"J Med Toxicol"},{"issue":"5","key":"3585_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.reaurg.2009.05.004","volume":"18","author":"B Megarbane","year":"2009","unstructured":"Megarbane B, Deye N, Baud FJ. Extracorporeal life support for acute poisonings with cardiotoxicants [French]. Reanimation. 2009;18(5):428\u201338.","journal-title":"Reanimation"},{"issue":"2","key":"3585_CR55","first-page":"1","volume":"16","author":"W Palatnick","year":"2014","unstructured":"Palatnick W, Jelic T. Emergency department management of calcium-channel blocker, beta blocker, and digoxin toxicity. Emerg Med Pract. 2014;16(2):1\u201319 (quiz -20).","journal-title":"Emerg Med Pract."},{"issue":"3","key":"3585_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bcp.12763","volume":"81","author":"A Graudins","year":"2016","unstructured":"Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3585_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/15563650.2017.1284329","volume":"55","author":"CA Skoog","year":"2017","unstructured":"Skoog CA, Engebretsen KM. Are vasopressors useful in toxin-induced cardiogenic shock? Clin Toxicol. 2017;55(4):285\u2013304.","journal-title":"Clin Toxicol"},{"issue":"5","key":"3585_CR58","first-page":"665","volume":"16","author":"K Daheb","year":"2013","unstructured":"Daheb K, Lipman ML, Hildgen P, Roy JJ. Artificial neural network modeling for drug dialyzability prediction. J Pharm Pharmaceut Sci. 2013;16(5):665\u201375.","journal-title":"J Pharm Pharmaceut Sci"},{"issue":"4","key":"3585_CR59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1365-2125.1983.tb01535.x","volume":"15","author":"A Heath","year":"1983","unstructured":"Heath A, Gabrielsson M, Redgardh CG. Absorption of beta-adrenoceptor antagonists to Amberlite resin. Br J Clin Pharmacol. 1983;15(4):490\u20132.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3585_CR60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000169307","volume":"2","author":"A Pauls","year":"1984","unstructured":"Pauls A, Grigoleit HG, Von Herrath D, Schaefer K. Comparison of drug elimination by current methods of blood purification. Blood Purif. 1984;2(1):14\u201322.","journal-title":"Blood Purif"},{"issue":"10","key":"3585_CR61","first-page":"742","volume":"41","author":"T Schneider","year":"1986","unstructured":"Schneider T, Siegmund W, Franke G, Kraatz G, Scherber A. The binding of propranolol, dihydralazine and selected metabolites to adsorbent resins for hemoperfusion. Pharmazie. 1986;41(10):742\u20133.","journal-title":"Pharmazie"},{"issue":"1","key":"3585_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF03189860","volume":"12","author":"A Celardo","year":"1987","unstructured":"Celardo A, Traina GL, Arboix M, Puigdemont A, Bonati M. Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. Eur J Drug Metab Pharmacokinet. 1987;12(1):41\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"3585_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0160-5402(86)90062-8","volume":"15","author":"GL Traina","year":"1986","unstructured":"Traina GL, Celardo A, Arboix M, Bonati M. Experimental model for pharmacokinetic studies during continuous peritoneal dialysis in the rabbit. J Pharmacol Methods. 1986;15(2):133\u201341.","journal-title":"J Pharmacol Methods"},{"issue":"3","key":"3585_CR64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jps.2600700336","volume":"70","author":"PR Gwilt","year":"1981","unstructured":"Gwilt PR. General equation for assessing drug removal by extracorporeal devices. J Pharm Sci. 1981;70(3):345\u20136.","journal-title":"J Pharm Sci"},{"issue":"5888","key":"3585_CR65","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bmj.4.5888.320","volume":"4","author":"JB Eastwood","year":"1973","unstructured":"Eastwood JB, Curtis JR, Smith RB. Pharmacodynamics of practolol in chronic renal failure. BMJ. 1973;4(5888):320\u20132.","journal-title":"BMJ"},{"issue":"5 Part 1","key":"3585_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cpt1974165part1761","volume":"16","author":"DT Lowenthal","year":"1974","unstructured":"Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ. Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther. 1974;16(5 Part 1):761\u20139.","journal-title":"Clin Pharmacol Ther."},{"issue":"8\u20139","key":"3585_CR67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/j.1552-4604.1975.tb02379.x","volume":"15","author":"C Harvengt","year":"1975","unstructured":"Harvengt C, Desager JP, Muschart JM, Tjandramaga YB, Verbeeck R, Verberckmoes R. Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure. J Clin Pharmacol. 1975;15(8\u20139):605\u201310.","journal-title":"J Clin Pharmacol"},{"issue":"46 Suppl","key":"3585_CR68","first-page":"3228","volume":"4","author":"A Roux","year":"1975","unstructured":"Roux A, Aubert P, Guedon J, Flouvat B. Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis. Nouv Presse Med. 1975;4(46 Suppl):3228\u201333.","journal-title":"Nouv Presse Med"},{"issue":"9","key":"3585_CR69","first-page":"799","volume":"82","author":"P Aubert","year":"1976","unstructured":"Aubert P, Roux A, Flouvat B, Lucsko M, Chaignon M, Guedon J. Pharmacokinetics of acebutolol in renal failure. J Urol Nephrol (Paris). 1976;82(9):799\u2013804.","journal-title":"J Urol Nephrol (Paris)"},{"issue":"5","key":"3585_CR70","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/00003088-197601050-00004","volume":"1","author":"G Bianchetti","year":"1976","unstructured":"Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, Manfrin M, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet. 1976;1(5):373\u201384.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3585_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2125.1976.tb00601.x","volume":"3","author":"TB Tjandramaga","year":"1976","unstructured":"Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJ. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol. 1976;3(2):259\u201365.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3585_CR72","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cpt1978235606","volume":"23","author":"DT Lowenthal","year":"1978","unstructured":"Lowenthal DT, Pitone JM, Affrime MB, Shirk J, Busby P, Kim KE, et al. Timolol kinetics in chronic renal insufficiency. Clin Pharmacol Ther. 1978;23(5):606\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"3585_CR73","first-page":"607","volume":"15","author":"W Niedermayer","year":"1978","unstructured":"Niedermayer W, Seiler KU, Wassermann O. Pharmacokinetics of antihypertensive drugs (atenolol, metoprolol, propranolol and clonidine) and their metabolites during intermittent haemodialysis in humans. Proc Eur Dial Transplant Assoc. 1978;15:607\u20139.","journal-title":"Proc Eur Dial Transplant Assoc"},{"issue":"1","key":"3585_CR74","first-page":"63","volume":"34","author":"B Flouvat","year":"1979","unstructured":"Flouvat B, Decourt S, Potaux L. Pharmacokinetics of propranolol in patients with chronic renal insufficiency undergoing hemodialysis. Therapie. 1979;34(1):63\u201372.","journal-title":"Therapie"},{"issue":"Suppl 2","key":"3585_CR75","doi-asserted-by":"publisher","first-page":"227S","DOI":"10.1111\/j.1365-2125.1979.tb04694.x","volume":"7","author":"J Herrera","year":"1979","unstructured":"Herrera J, Vukovich RA, Griffith DL. Elimination of nadolol by patients with renal impairment. Br J Clin Pharmacol. 1979;7(Suppl 2):227S-S231.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3585_CR76","first-page":"176","volume":"239","author":"MT Rosseel","year":"1979","unstructured":"Rosseel MT, Bogaert MG, Christiaens M, Verpooten GA, De Broe ME. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease. Arch Int Pharmacodyn Ther. 1979;239(1):176.","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"1","key":"3585_CR77","first-page":"124","volume":"10","author":"RR Bailey","year":"1980","unstructured":"Bailey RR, Munn SR, Begg E. The pharmacokinetics of acebutolol in patients with renal functional impairment. Aust N Z J Med. 1980;10(1):124.","journal-title":"Aust N Z J Med"},{"issue":"4","key":"3585_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2125.1980.tb01065.x","volume":"9","author":"B Flouvat","year":"1980","unstructured":"Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, et al. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol. 1980;9(4):379\u201385.","journal-title":"Br J Clin Pharmacol"},{"key":"3585_CR79","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/978-3-642-67729-8_79","volume":"4","author":"W Kirch","year":"1980","unstructured":"Kirch W, Schafer M, Braun M. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis. Arch Toxicol Suppl. 1980;4:366\u20139.","journal-title":"Arch Toxicol Suppl"},{"issue":"5","key":"3585_CR80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00558446","volume":"17","author":"A Roux","year":"1980","unstructured":"Roux A, Aubert P, Guedon J, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980;17(5):339\u201348.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR81","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/clpt.1980.105","volume":"27","author":"DW Schneck","year":"1980","unstructured":"Schneck DW, Pritchard JF, Gibson TP, Vary JE, Hayes AH Jr. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. Clin Pharmacol Ther. 1980;27(6):744\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR82","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003088-198005020-00006","volume":"5","author":"KU Seiler","year":"1980","unstructured":"Seiler KU, Schuster KJ, Meyer GJ, Niedermayer W, Wassermann O. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5(2):192\u20138.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3585_CR83","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/clpt.1981.63","volume":"29","author":"AD Blair","year":"1981","unstructured":"Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther. 1981;29(4):457\u201363.","journal-title":"Clin Pharmacol Ther"},{"issue":"49","key":"3585_CR84","first-page":"1915","volume":"111","author":"P Dayer","year":"1981","unstructured":"Dayer P, Glasson P, Gorgia A, Balant L, Fabre J. Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency. Schweizerische medizinische Wochenschrift. 1981;111(49):1915\u20138.","journal-title":"Schweizerische medizinische Wochenschrift"},{"issue":"1","key":"3585_CR85","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00558387","volume":"19","author":"W Kirch","year":"1981","unstructured":"Kirch W, Kohler H, Mutschler E, Schafer M. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol. 1981;19(1):65\u201371.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3585_CR86","first-page":"142","volume":"3","author":"JL Bouchet","year":"1982","unstructured":"Bouchet JL, Pocheville M, Alsabbach M. Betaxolol pharmacokinetics in chronic renal failure, hemodialysis and CAPD [French]. Nephrologie. 1982;3(3):142.","journal-title":"Nephrologie"},{"key":"3585_CR87","unstructured":"Kawasaki T, Ueno M, Uezono K, Abe I, Kawazoe N, Omae T, et al. Blood levels of long-acting propranolol in normal subjects and patients with renal failure. Fukuoka igaku zasshi = Hukuoka acta medica. 1983;74 (11):737\u201343."},{"issue":"4","key":"3585_CR88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF00549590","volume":"27","author":"W Krause","year":"1984","unstructured":"Krause W, Kampf D, Fischer HC. Pharmacokinetics of mepindolol in patients with chronic renal failure. Eur J Clin Pharmacol. 1984;27(4):429\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4 Pt 2","key":"3585_CR89","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0002-8703(84)90587-8","volume":"108","author":"RS Michaels","year":"1984","unstructured":"Michaels RS, Duchin KL, Akbar S, Meister J, Levin NW. Nadolol in hypertensive patients maintained on long-term hemodialysis. Am Heart J. 1984;108(4 Pt 2):1091\u20134.","journal-title":"Am Heart J"},{"issue":"3","key":"3585_CR90","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-2125.1984.tb02490.x","volume":"18","author":"AK Salahudeen","year":"1984","unstructured":"Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Br J Clin Pharmacol. 1984;18(3):457\u201360.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3585_CR91","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/j.1552-4604.1985.tb02864.x","volume":"25","author":"VM Campese","year":"1985","unstructured":"Campese VM, Feinstein EI, Gura V, Mason WD, Massry SG. Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis. J Clin Pharmacol. 1985;25(5):393\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3585_CR92","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/clpt.1986.207","volume":"40","author":"CE Halstenson","year":"1986","unstructured":"Halstenson CE, Opsahl JA, Pence TV, Luke DR, Sirgo MA, Plachetka JR, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40(4):462\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl M","key":"3585_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurheartj\/8.suppl_M.15","volume":"8","author":"CD Payton","year":"1987","unstructured":"Payton CD, Fox JG, Pauleau NF, Boulton-Jones JM, Ioannides C, Johnston A, et al. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance. Eur Heart J. 1987;8(Suppl M):15\u201322.","journal-title":"Eur Heart J"},{"issue":"2","key":"3585_CR94","first-page":"141","volume":"42","author":"V Gasparovic","year":"1988","unstructured":"Gasparovic V, Milutinovic S, Plavsic F, Gjurasin M, Molnar V. Pharmacokinetics of labetalol in patients on hemodialysis. Acta Med Iugosl. 1988;42(2):141\u20135.","journal-title":"Acta Med Iugosl"},{"issue":"3","key":"3585_CR95","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/clpt.1989.35","volume":"45","author":"JF Flaherty","year":"1989","unstructured":"Flaherty JF, Wong B, La Follette G, Warnock DG, Hulse JD, Gambertoglio JG. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther. 1989;45(3):321\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 4","key":"3585_CR96","first-page":"S62","volume":"18","author":"S Miki","year":"1991","unstructured":"Miki S, Masumura H, Kaifu Y, Yuasa S. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol. 1991;18(Suppl 4):S62\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3585_CR97","first-page":"285","volume":"37","author":"J Motan","year":"1991","unstructured":"Motan J, Mayer O, Spanel M. Kinetics of metipranolol in patients with chronic kidney failure and during hemodialysis. Vnitr Lek. 1991;37(3):285\u201392.","journal-title":"Vnitr Lek"},{"issue":"12","key":"3585_CR98","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1177\/039139889902201204","volume":"22","author":"K Kanegae","year":"1999","unstructured":"Kanegae K, Hiroshige K, Suda T, Iwamoto M, Ohta T, Nakashima Y, et al. Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension. Int J Artif Organs. 1999;22(12):798\u2013804.","journal-title":"Int J Artif Organs"},{"issue":"2","key":"3585_CR99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5414\/CPP39061","volume":"39","author":"M Krueger","year":"2001","unstructured":"Krueger M, Achenbach H, Terhaag B, Haase H, Richter K, Oertel R, et al. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. Int J Clin Pharmacol Ther. 2001;39(2):61\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"3585_CR100","first-page":"657","volume":"16","author":"K Daheb","year":"2013","unstructured":"Daheb K, Lecours JP, Lipman ML, Hildgen P, Roy JJ. Prediction of in vivo atenolol removal by high-permeability hemodialysis based on an in vitro model. J Pharm Pharmaceut Sci. 2013;16(5):657\u201364.","journal-title":"J Pharm Pharmaceut Sci"},{"issue":"4","key":"3585_CR101","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2215\/CJN.07470717","volume":"13","author":"A Tieu","year":"2018","unstructured":"Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL. beta-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial. Clin J Am Soc Nephrol CJASN. 2018;13(4):604\u201311.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"24","key":"3585_CR102","first-page":"963","volume":"36","author":"G Stein","year":"1981","unstructured":"Stein G, Demme U, Sperschneider H, Funfstuck R, Werner R, Meier F, et al. Detoxication by hemoperfusion. Z Gesamte Inn Med. 1981;36(24):963\u20139.","journal-title":"Z Gesamte Inn Med"},{"key":"3585_CR103","unstructured":"Garrasch B, Presber G, Lindau K. Contribution to intoxication with beta-adrenergic blocking agents. [German]. Anaesthesiologie und Reanimation. 1983;8 (5):279\u201386."},{"key":"3585_CR104","first-page":"1459","volume":"38","author":"H von Thieler","year":"1983","unstructured":"von Thieler H, Oltmanns G, Wehren JH. Hemoperfusion in acute talinolol intoxication. Dt Gesundh-Wesen. 1983;38:1459\u201361.","journal-title":"Dt Gesundh-Wesen"},{"issue":"3","key":"3585_CR105","first-page":"273","volume":"4","author":"Y Bouffard","year":"1984","unstructured":"Bouffard Y, Ritter J, Delafosse B. Atenolol intoxication: Study of one case with plasmatic analysis [French]. J Toxicol Med. 1984;4(3):273\u20137.","journal-title":"J Toxicol Med"},{"issue":"11","key":"3585_CR106","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0196-0644(86)80622-9","volume":"15","author":"T Anthony","year":"1986","unstructured":"Anthony T, Jastremski M, Elliott W, Morris G, Prasad H. Charcoal hemoperfusion for the treatment of a combined diltiazem and metoprolol overdose. Ann Emerg Med. 1986;15(11):1344\u20138.","journal-title":"Ann Emerg Med"},{"key":"3585_CR107","first-page":"1463","volume":"42","author":"B Terhaag","year":"1987","unstructured":"Terhaag B, Grunert A, Richter K, Bahlmann G, Glaris A. Effectiveness of hemoperfusion in talinolol overdose\u2014a case report. Z Klin Med. 1987;42:1463\u20136.","journal-title":"Z Klin Med"},{"issue":"5\u20136","key":"3585_CR108","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/15563658809167103","volume":"26","author":"D Perrot","year":"1988","unstructured":"Perrot D, Bui-Xuan B, Lang J, Bouffard Y, Delafosse B, Faucon G, et al. A case of sotalol poisoning with fatal outcome. J Toxicol Clin Toxicol. 1988;26(5\u20136):389\u201396.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"6","key":"3585_CR109","first-page":"307","volume":"26","author":"P Lenga","year":"1989","unstructured":"Lenga P, Odenthal HJ, Josephs W, Rawert B, Schilken P, Wiechmann HW. Treatment of an intoxication with acebutolol by hemoperfusion. Case report on a severe self poisoning. Intensivmedizin und Notfallmedizin. 1989;26(6):307\u201311.","journal-title":"Intensivmedizin und Notfallmedizin"},{"issue":"2","key":"3585_CR110","first-page":"157","volume":"44","author":"G Rostock","year":"1989","unstructured":"Rostock G, Kinzel W. Concentrations of propranolol (Obsidan) in blood of patients with intoxications. Zeitschrift fur Klinische Medizin. 1989;44(2):157\u201360.","journal-title":"Zeitschrift fur Klinische Medizin"},{"issue":"1","key":"3585_CR111","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00003246-199101000-00026","volume":"19","author":"R Saitz","year":"1991","unstructured":"Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med. 1991;19(1):116\u20138.","journal-title":"Crit Care Med"},{"issue":"1","key":"3585_CR112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1051\/ject\/199224136","volume":"24","author":"CD Welch","year":"1992","unstructured":"Welch CD, Knoerzer RE, Lewis GS. Verapamil and acebutolol overdose results in asystole: intra-aortic balloon pump provides mechanical support. J Extra-Corporeal Technol. 1992;24(1):36\u20137.","journal-title":"J Extra-Corporeal Technol"},{"issue":"8","key":"3585_CR113","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/j.1552-4604.1996.tb04247.x","volume":"36","author":"M Rooney","year":"1996","unstructured":"Rooney M, Massey KL, Jamali F, Rosin M, Thomson D, Johnson DH. Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. J Clin Pharmacol. 1996;36(8):760\u20133.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3585_CR114","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/089686089701700223","volume":"17","author":"S Tang","year":"1997","unstructured":"Tang S, Lo CY, Lo WK, Tai YT, Chan TM. Sotalol-induced torsade de pointes in a CAPD patient\u2014successful treatment with intermittent peritoneal dialysis. Perit Dial Int. 1997;17(2):207\u20138.","journal-title":"Perit Dial Int"},{"issue":"2","key":"3585_CR115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/12.2.331","volume":"12","author":"SH van Uum","year":"1997","unstructured":"van Uum SH, van den Merkhof LF, Lucassen AM, Wuis EW, Diemont W. Successful haemodialysis in sotalol-induced torsade de pointes in a patient with progressive renal failure. Nephrol Dial Transplant. 1997;12(2):331\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"3585_CR116","first-page":"70A","volume":"44","author":"H Stein","year":"1998","unstructured":"Stein H, Sirota R, Snipes E, Gronich J, Collins D. Acute hemodialysis for sotalol HCL intoxication (ASAIO Journal (March\/April 1998) 44 (70A)). ASAIO J. 1998;44:70A.","journal-title":"ASAIO J"},{"issue":"2","key":"3585_CR117","first-page":"83","volume":"11","author":"Z Bergl","year":"2000","unstructured":"Bergl Z, Simecek V. Protracted cardiopulmonary resuscitation in patient intoxicated with lethal dose of beta-blocker Sectral [Czech]. Anesteziologie a Neodkladna Pece. 2000;11(2):83\u20134.","journal-title":"Anesteziologie a Neodkladna Pece."},{"issue":"4","key":"3585_CR118","first-page":"224","volume":"42","author":"SD Salhanick","year":"2000","unstructured":"Salhanick SD, Wax PM. Treatment of atenolol overdose in a patient with renal failure using serial hemodialysis and hemoperfusion and associated echocardiographic findings. Vet Hum Toxicol. 2000;42(4):224\u20135.","journal-title":"Vet Hum Toxicol"},{"issue":"6","key":"3585_CR119","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/0885066607307528","volume":"22","author":"J Kolcz","year":"2007","unstructured":"Kolcz J, Pietrzyk J, Januszewska K, Procelewska M, Mroczek T, Malec E. Extracorporeal life support in severe propranolol and verapamil intoxication. J Intensive Care Med. 2007;22(6):381\u20135.","journal-title":"J Intensive Care Med"},{"issue":"3","key":"3585_CR120","first-page":"97","volume":"74","author":"M Pfaender","year":"2008","unstructured":"Pfaender M, Casetti PG, Azzolini M, Baldi ML, Valli A. Successful treatment of a massive atenolol and nifedipine overdose with CVVHDF. Minerva Anestesiol. 2008;74(3):97\u2013100.","journal-title":"Minerva Anestesiol"},{"issue":"7","key":"3585_CR121","first-page":"603","volume":"46","author":"C Zebuda","year":"2008","unstructured":"Zebuda C, Majilesi N, Greller HA, Lee DC, Su MK, Chan GM. Sotalol-induced tosades de pointes treated wtih hemodialysis. Clin Toxicol. 2008;46(7):603.","journal-title":"Clin Toxicol"},{"issue":"3","key":"3585_CR122","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3109\/15563650903544132","volume":"48","author":"VC Mulder","year":"2010","unstructured":"Mulder VC, Oudemans-Van Straaten HM, Zandstra DF, Franssen EJ. Massive ingestion of cardiac drugs: toxicokinetic aspects of digoxin and sotalol during hemofiltration. Clin Toxicol (Phila). 2010;48(3):218\u201321.","journal-title":"Clin Toxicol (Phila)"},{"key":"3585_CR123","doi-asserted-by":"crossref","unstructured":"Rona R, Cortinovis B, Marcolin R, Patroniti N, Isgr S, Marelli C, et al. Extra-corporeal life support for near-fatal multi-drug intoxication: A case report. Journal of Medical Case Reports. 2011;5 (no pagination) (231).","DOI":"10.1186\/1752-1947-5-231"},{"issue":"4","key":"3585_CR124","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/hdi.12020","volume":"17","author":"SH Huang","year":"2013","unstructured":"Huang SH, Tirona RG, Ross C, Suri RS. Case report: atenolol overdose successfully treated with hemodialysis. Hemodialysis international International Symposium on Home Hemodialysis. 2013;17(4):652\u20135.","journal-title":"Hemodialysis international International Symposium on Home Hemodialysis"},{"issue":"3","key":"3585_CR125","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0972-5229.128709","volume":"18","author":"A Garg","year":"2014","unstructured":"Garg A, Panda S, Dalvi P, Mehra S, Ray S, Singh VK. Severe suicidal digoxin and propranolol toxicity with insulin overdose. Indian J Crit Care Med. 2014;18(3):173\u20135.","journal-title":"Indian J Crit Care Med"},{"issue":"5","key":"3585_CR126","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jemermed.2014.04.044","volume":"47","author":"R Koschny","year":"2014","unstructured":"Koschny R, Lutz M, Seckinger J, Schwenger V, Stremmel W, Eisenbach C. Extracorporeal life support and plasmapheresis in a case of severe polyintoxication. J Emerg Med. 2014;47(5):527\u201331.","journal-title":"J Emerg Med"},{"issue":"5","key":"3585_CR127","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/0971-4065.133033","volume":"24","author":"P Sandeep","year":"2014","unstructured":"Sandeep P, Ram R, Sowgandhi N, Reddy SA, Katyarmal DT, Kumar BS, et al. Atenolol and amlodipine combination overdose managed with continuous venovenous hemodiafiltration: a case report. Indian J Nephrol. 2014;24(5):327\u20139.","journal-title":"Indian J Nephrol"},{"issue":"1","key":"3585_CR128","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s13181-014-0419-y","volume":"11","author":"CW Heise","year":"2015","unstructured":"Heise CW, Beutler D, Bosak A, Orme G, Loli A, Graeme K. Massive atenolol, lisinopril, and chlorthalidone overdose treated with endoscopic decontamination, hemodialysis, impella percutaneous left ventricular assist device, and ECMO. J Med Toxicol. 2015;11(1):110\u20134.","journal-title":"J Med Toxicol"},{"key":"3585_CR129","doi-asserted-by":"crossref","unstructured":"Seegobin K, Maharaj S, Deosaran A, Reddy P. Severe beta blocker and calcium channel blocker overdose: Role of high dose insulin. Am J Emerg Med. 2018;36 (4):736 e5-e6.","DOI":"10.1016\/j.ajem.2018.01.038"},{"issue":"2","key":"3585_CR130","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1024907918762868","volume":"26","author":"LW Chen","year":"2019","unstructured":"Chen LW, Mao DR, Chen YS. Extracorporeal life support: the final \u201cantidote\u201d for massive propranolol overdose. Hong Kong J Emerg Med. 2019;26(2):118\u201323.","journal-title":"Hong Kong J Emerg Med"},{"issue":"12","key":"3585_CR131","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/106002808101501215","volume":"15","author":"RL Talbert","year":"1981","unstructured":"Talbert RL, Wong YY, Duncan DB. Propranolol plasma concentrations and plasmapheresis. Drug Intell Clin Pharm. 1981;15(12):993\u20136.","journal-title":"Drug Intell Clin Pharm"},{"issue":"4","key":"3585_CR132","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/sdi.12251","volume":"27","author":"V Lavergne","year":"2014","unstructured":"Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial. 2014;27(4):407\u201314.","journal-title":"Semin Dial"},{"issue":"4","key":"3585_CR133","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/ndt\/gfw456","volume":"32","author":"J Bouchard","year":"2017","unstructured":"Bouchard J, Lavergne V, Roberts DM, Cormier M, Morissette G, Ghannoum M. Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey. Nephrol Dial Transplant. 2017;32(4):699\u2013706.","journal-title":"Nephrol Dial Transplant"},{"issue":"16","key":"3585_CR134","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","volume":"289","author":"SM Al-Khatib","year":"2003","unstructured":"Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120\u20137.","journal-title":"JAMA"},{"issue":"3","key":"3585_CR135","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jacc.2006.08.057","volume":"49","author":"AJ Sauer","year":"2007","unstructured":"Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49(3):329\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3585_CR136","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/cpt1977216691","volume":"21","author":"A Amery","year":"1977","unstructured":"Amery A, De Plaen JF, Lijnen P, McAinsh J, Reybrouck T. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 1977;21(6):691\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR137","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/sdi.12247","volume":"27","author":"J Bouchard","year":"2014","unstructured":"Bouchard J, Roberts DM, Roy L, Ouellet G, Decker BS, Mueller BA, et al. Principles and operational parameters to optimize poison removal with extracorporeal treatments. Semin Dial. 2014;27(4):371\u201380.","journal-title":"Semin Dial"},{"key":"3585_CR138","unstructured":"Decourt S, Roux A, Baglin A, Domart M, Aubert P, Flouvat B, et al. Study of the binding of beta blockers to plasma proteins. Therapeutic consequences. Acquis Med Recent. 1977:181\u201394."},{"issue":"4","key":"3585_CR139","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cpt1976194416","volume":"19","author":"CM Kaye","year":"1976","unstructured":"Kaye CM, Kumana CR, Leighton M, Hamer J, Turner P. Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther. 1976;19(4):416\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3585_CR140","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000213115","volume":"29","author":"A Roux","year":"1983","unstructured":"Roux A, Henry JF, Fouache Y, Chau NP, Hervy MP, Forette F, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983;29(3):202\u20138.","journal-title":"Gerontology"},{"issue":"3","key":"3585_CR141","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bdd.2510040309","volume":"4","author":"A Roux","year":"1983","unstructured":"Roux A, Flouvat B, Fouache Y, Bourdarias JP. Systemic bioavailability of acebutolol in man. Biopharm Drug Dispos. 1983;4(3):293\u20137.","journal-title":"Biopharm Drug Dispos"},{"issue":"46 Suppl","key":"3585_CR142","first-page":"3223","volume":"4","author":"RF Collins","year":"1975","unstructured":"Collins RF. Pharmacokinetics of acebutolol. Nouv Presse Med. 1975;4(46 Suppl):3223\u20138.","journal-title":"Nouv Presse Med"},{"issue":"2","key":"3585_CR143","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2125.1980.tb05837.x","volume":"9","author":"A Roux","year":"1980","unstructured":"Roux A, Flouvat B, Chau NP, Letac B, Lucsko M. Pharmacokinetics of acebutolol after intravenous bolus administration. Br J Clin Pharmacol. 1980;9(2):215\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR144","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2125.1983.tb02158.x","volume":"16","author":"RS Smith","year":"1983","unstructured":"Smith RS, Warren DJ, Renwick AG, George CF. Acebutolol pharmacokinetics in renal failure. Br J Clin Pharmacol. 1983;16(3):253\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR145","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2125.1979.tb04644.x","volume":"7","author":"SH Wan","year":"1979","unstructured":"Wan SH, Koda RT, Maronde RF. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol. 1979;7(6):569\u201374.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3585_CR146","first-page":"88","volume":"18","author":"W Kirch","year":"1982","unstructured":"Kirch W, Kohler H, Berggren G, Braun W. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. Clin Nephrol. 1982;18(2):88\u201394.","journal-title":"Clin Nephrol"},{"issue":"658","key":"3585_CR147","first-page":"289","volume":"91","author":"S Munn","year":"1980","unstructured":"Munn S, Bailey RR, Begg E, Ebert R, Ferry DG. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. N Z Med J. 1980;91(658):289\u201391.","journal-title":"N Z Med J"},{"issue":"1","key":"3585_CR148","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","volume":"24","author":"M Schulz","year":"2020","unstructured":"Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195.","journal-title":"Crit Care"},{"issue":"1","key":"3585_CR149","first-page":"59","volume":"8","author":"R Johansson","year":"1971","unstructured":"Johansson R, Regardh CG, Sjogren J. Absorption of alprenolol in man from tablets with different rates of release. Acta Pharm Suec. 1971;8(1):59\u201370.","journal-title":"Acta Pharm Suec"},{"issue":"7","key":"3585_CR150","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/chir.10097","volume":"14","author":"H Imamura","year":"2002","unstructured":"Imamura H, Komori T, Ismail A, Suenaga A, Otagiri M. Stereoselective protein binding of alprenolol in the renal diseased state. Chirality. 2002;14(7):599\u2013603.","journal-title":"Chirality"},{"issue":"3","key":"3585_CR151","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01065395","volume":"5","author":"G Alvan","year":"1977","unstructured":"Alvan G, Lind M, Mellstrom B, von Bahr C. Importance of \u201cfirst-pass elimination\u201d for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol. J Pharmacokinet Biopharm. 1977;5(3):193\u2013205.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"3585_CR152","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1600-0773.1974.tb00745.x","volume":"35","author":"NO Bodin","year":"1974","unstructured":"Bodin NO, Borg KO, Johansson R, Obianwu H, Svensson R. Absorption, distribution and excretion of alprenolol in man, dog and rat. Acta Pharmacol Toxicol (Copenh). 1974;35(4):261\u20139.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"4","key":"3585_CR153","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0024-3205(74)90452-4","volume":"14","author":"B Ablad","year":"1974","unstructured":"Ablad B, Borg KO, Johnsson G, Regardh CG, Solvell L. Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sci. 1974;14(4):693\u2013704.","journal-title":"Life Sci"},{"issue":"6","key":"3585_CR154","first-page":"635","volume":"37","author":"S Decourt","year":"1982","unstructured":"Decourt S, Roux A, Baglin A, Aubert P, Prinseau J, Flouvat B. Influence of protein binding on dialysis clearance of several beta-blocking agents in chronically hemodialysed patients. Therapie. 1982;37(6):635\u201340.","journal-title":"Therapie"},{"issue":"4","key":"3585_CR155","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpt1979254408","volume":"25","author":"WD Mason","year":"1979","unstructured":"Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979;25(4):408\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3585_CR156","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/clpt.1980.166","volume":"28","author":"J McAinsh","year":"1980","unstructured":"McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980;28(3):302\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR157","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.1982.tb01364.x","volume":"13","author":"PC Rubin","year":"1982","unstructured":"Rubin PC, Scott PJ, McLean K, Pearson A, Ross D, Reid JL. Atenolol disposition in young and elderly subjects. Br J Clin Pharmacol. 1982;13(2):235\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3585_CR158","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/j.1552-4604.1983.tb02721.x","volume":"23","author":"W Kirch","year":"1983","unstructured":"Kirch W, Schafer-Korting M, Mutschler E, Ohnhaus EE, Braun W. Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmacol. 1983;23(4):171\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3585_CR159","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/clpt.1989.198","volume":"46","author":"ML Buck","year":"1989","unstructured":"Buck ML, Wiest D, Gillette PC, Trippel D, Krull J, O\u2019Neal W. Pharmacokinetics and pharmacodynamics of atenolol in children. Clin Pharmacol Ther. 1989;46(6):629\u201333.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR160","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00609750","volume":"13","author":"JD Fitzgerald","year":"1978","unstructured":"Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978;13(2):81\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3585_CR161","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/cpt1976205524","volume":"20","author":"HC Brown","year":"1976","unstructured":"Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, et al. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976;20(5):524\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3585_CR162","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF00609856","volume":"12","author":"J Sassard","year":"1977","unstructured":"Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol. 1977;12(3):175\u201380.","journal-title":"Eur J Clin Pharmacol"},{"key":"3585_CR163","doi-asserted-by":"crossref","unstructured":"el-Yazigi A, Bouchama A, al-Abdely H, Yusuf A, Sieck JO. Impaired elimination of atenolol in a nephropathic patient with self-medication overdose. J Clin Pharmacol. 1993;33 (5):450\u20132.","DOI":"10.1002\/j.1552-4604.1993.tb04686.x"},{"issue":"5","key":"3585_CR164","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2125.1980.tb01787.x","volume":"10","author":"SJ Warrington","year":"1980","unstructured":"Warrington SJ, Turner P, Kilborn JR, Bianchetti G, Morselli PL. Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol. 1980;10(5):449\u201352.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3585_CR165","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jps.2600770913","volume":"77","author":"TM Ludden","year":"1988","unstructured":"Ludden TM, Boyle DA, Gieseker D, Kennedy GT, Crawford MH, Ludden LK, et al. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects. J Pharm Sci. 1988;77(9):779\u201383.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3585_CR166","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00606665","volume":"31","author":"G Bianchetti","year":"1986","unstructured":"Bianchetti G, Thiercelin JF, Thenot JP. Pharmacokinetics of betaxolol in middle aged patients. Eur J Clin Pharmacol. 1986;31(2):231\u20133.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3585_CR167","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jps.2600800407","volume":"80","author":"G Stagni","year":"1991","unstructured":"Stagni G, Davis PJ, Ludden TM. Human pharmacokinetics of betaxolol enantiomers. J Pharm Sci. 1991;80(4):321\u20134.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3585_CR168","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/clpt.1984.19","volume":"35","author":"R Palminteri","year":"1984","unstructured":"Palminteri R, Assael BM, Bianchetti G, Gomeni R, Claris-Appiani A, Edefonti A, et al. Betaxolol kinetics in hypertensive children with normal and abnormal renal function. Clin Pharmacol Ther. 1984;35(2):141\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR169","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2165\/00003088-198713020-00003","volume":"13","author":"W Kirch","year":"1987","unstructured":"Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987;13(2):110\u20137.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3585_CR170","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/j.1552-4604.1986.tb02959.x","volume":"26","author":"G Leopold","year":"1986","unstructured":"Leopold G, Pabst J, Ungethum W, Buhring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol. 1986;26(8):616\u201321.","journal-title":"J Clin Pharmacol"},{"key":"3585_CR171","doi-asserted-by":"crossref","unstructured":"Hayes PC, Jenkins D, Vavianos P, Dagap K, Johnston A, Ioannides C, et al. Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease. Eur Heart J. 1987;8 Suppl M:23\u20139.","DOI":"10.1093\/eurheartj\/8.suppl_M.23"},{"issue":"2","key":"3585_CR172","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00265912","volume":"41","author":"C Le Jeunne","year":"1991","unstructured":"Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol. 1991;41(2):171\u20134.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3585_CR173","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-016-2041-1","volume":"72","author":"K Cvan Trobec","year":"2016","unstructured":"Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, et al. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol. 2016;72(7):813\u201322.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR174","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00005344-199107000-00005","volume":"18","author":"F Le Coz","year":"1991","unstructured":"Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, et al. Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers. J Cardiovasc Pharmacol. 1991;18(1):28\u201334.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3585_CR175","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00228-012-1427-y","volume":"69","author":"VN Nikolic","year":"2013","unstructured":"Nikolic VN, Jevtovic-Stoimenov T, Velickovic-Radovanovic R, Ilic S, Deljanin-Ilic M, Marinkovic D, et al. Population pharmacokinetics of bisoprolol in patients with chronic heart failure. Eur J Clin Pharmacol. 2013;69(4):859\u201365.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR176","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2125.1991.tb05596.x","volume":"31","author":"NJ MacDonald","year":"1991","unstructured":"MacDonald NJ, Grant AC, Rodger RS, Meredith PA, Elliott HL. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. Br J Clin Pharmacol. 1991;31(6):697\u2013700.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3585_CR177","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2125.1986.tb02821.x","volume":"21","author":"WH Aellig","year":"1986","unstructured":"Aellig WH, Nuesch E, Engel G, Grevel J, Niederberger W, Rosenthaler J. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade\u2013a study with oral and intravenous bopindolol. Br J Clin Pharmacol. 1986;21(1):45\u201351.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3585_CR178","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/clpt.1984.130","volume":"36","author":"R Platzer","year":"1984","unstructured":"Platzer R, Galeazzi RL, Niederberger W, Rosenthaler J. Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther. 1984;36(1):5\u201313.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3585_CR179","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/BF00316097","volume":"39","author":"G Wensing","year":"1990","unstructured":"Wensing G, Branch RA, Humbert H, Ohnhaus EE, Kirch W. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. Eur J Clin Pharmacol. 1990;39(6):569\u201372.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR180","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF00265913","volume":"41","author":"D Holmes","year":"1991","unstructured":"Holmes D, Nuesch E, Houle JM, Rosenthaler J. Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men. Eur J Clin Pharmacol. 1991;41(2):175\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR181","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00544023","volume":"25","author":"T Ishizaki","year":"1983","unstructured":"Ishizaki T, Ohnishi A, Sasaki T, Kushida K, Horai Y, Chiba K, et al. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. Eur J Clin Pharmacol. 1983;25(1):95\u2013101.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3585_CR182","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF00613462","volume":"29","author":"G Hasenfuss","year":"1985","unstructured":"Hasenfuss G, Schafer-Korting M, Knauf H, Mutschler E, Just H. Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol. 1985;29(4):461\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2a","key":"3585_CR183","first-page":"286","volume":"33","author":"W Lang","year":"1983","unstructured":"Lang W. Animal experimental studies on the pharmacokinetics of carteolol. Arzneimittelforschung. 1983;33(2a):286\u20139.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"3585_CR184","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF00544245","volume":"33","author":"E von Mollendorff","year":"1987","unstructured":"von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987;33(5):511\u20133.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"3585_CR185","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1007\/BF01409476","volume":"38","author":"G Neugebauer","year":"1990","unstructured":"Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol. 1990;38(Suppl 2):S108\u201311.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 11","key":"3585_CR186","first-page":"S89","volume":"10","author":"WJ Louis","year":"1987","unstructured":"Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S89-93.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"3585_CR187","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1097\/00005344-198710111-00015","volume":"10","author":"G Neugebauer","year":"1987","unstructured":"Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S85\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"3585_CR188","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1097\/00005344-199219001-00020","volume":"19","author":"H Masumura","year":"1992","unstructured":"Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S102\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3585_CR189","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s002280050628","volume":"55","author":"TW Gehr","year":"1999","unstructured":"Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999;55(4):269\u201377.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR190","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF02280760","volume":"43","author":"BK Kramer","year":"1992","unstructured":"Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. Eur J Clin Pharmacol. 1992;43(1):85\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR191","first-page":"50","volume":"33","author":"G Hitzenberger","year":"1983","unstructured":"Hitzenberger G, Takacs F, Pittner H. Pharmacokinetics of the beta adrenergic blocking substance celiprolol after single intravenous and oral administration in man. Arzneimittelforschung. 1983;33(1):50\u20132.","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"3585_CR192","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2165\/00003495-198734040-00002","volume":"34","author":"JG Riddell","year":"1987","unstructured":"Riddell JG, Shanks RG, Brogden RN. Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs. 1987;34(4):438\u201358.","journal-title":"Drugs"},{"key":"3585_CR193","first-page":"12","volume":"40","author":"FS Caruso","year":"1985","unstructured":"Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES. Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract Suppl. 1985;40:12\u20136.","journal-title":"Br J Clin Pract Suppl"},{"issue":"18","key":"3585_CR194","first-page":"729","volume":"97","author":"P Schmidt","year":"1985","unstructured":"Schmidt P, Takacs F, Pittner H, Minar E, Balcke P, Zazgornik J, et al. Comparative pharmacokinetics of the beta-1 receptor blookader celiprolol after a single oral administration in subjects with health kidneys and in patients with impaired renal function. Wien Klin Wochenschr. 1985;97(18):729\u201332.","journal-title":"Wien Klin Wochenschr"},{"issue":"Suppl 4","key":"3585_CR195","first-page":"S91","volume":"8","author":"RJ Norris","year":"1986","unstructured":"Norris RJ, Lee EH, Muirhead D, Sanders SW. A pharmacokinetic evaluation of celiprolol in healthy elderly volunteers. J Cardiovasc Pharmacol. 1986;8(Suppl 4):S91\u20132.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"3585_CR196","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0378-4347(00)82586-4","volume":"496","author":"C Hartmann","year":"1989","unstructured":"Hartmann C, Krauss D, Spahn H, Mutschler E. Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection. J Chromatogr. 1989;496(2):387\u201396.","journal-title":"J Chromatogr"},{"issue":"4","key":"3585_CR197","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/jaoac\/84.4.1252","volume":"84","author":"HS Savale","year":"2001","unstructured":"Savale HS, Pandya KK, Gandhi TP, Modi IA, Modi RI, Satia MC. Plasma analysis of celiprolol by HPTLC: a useful technique for pharmacokinetic studies. J AOAC Int. 2001;84(4):1252\u20137.","journal-title":"J AOAC Int"},{"issue":"3","key":"3585_CR198","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1067\/mcp.2003.26","volume":"73","author":"JJ Lilja","year":"2003","unstructured":"Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73(3):192\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3585_CR199","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clpt.2003.11.002","volume":"75","author":"JJ Lilja","year":"2004","unstructured":"Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther. 2004;75(3):184\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3585_CR200","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00228-003-0694-z","volume":"59","author":"JJ Lilja","year":"2004","unstructured":"Lilja JJ, Niemi M, Neuvonen PJ. Rifampicin reduces plasma concentrations of celiprolol. Eur J Clin Pharmacol. 2004;59(11):819\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3585_CR201","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/j.1552-4604.1988.tb05762.x","volume":"28","author":"VA Skoutakis","year":"1988","unstructured":"Skoutakis VA, Acchiardo SA, Carter CA, Ingebretsen CG, Klausner MA, Lee DK, et al. Pharmacokinetics of cetamolol in hypertensive patients with normal and compromised renal function. J Clin Pharmacol. 1988;28(5):467\u201376.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3585_CR202","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2125.1985.tb02663.x","volume":"19","author":"J Coelho","year":"1985","unstructured":"Coelho J, Schnelle K, Joubert L, Ventura D, Mullane J. Dynamics of beta-adrenoceptor blockade with cetamolol. Br J Clin Pharmacol. 1985;19(4):411\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR203","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0009-9120(84)80150-2","volume":"17","author":"MD Stern","year":"1984","unstructured":"Stern MD. Radioreceptor assay for serum levels of cetamolol, a new beta-adrenoceptor antagonist. Clin Biochem. 1984;17(3):162\u20135.","journal-title":"Clin Biochem"},{"issue":"4","key":"3585_CR204","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/clpt.1983.193","volume":"34","author":"CY Sum","year":"1983","unstructured":"Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther. 1983;34(4):427\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3585_CR205","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/j.1552-4604.1987.tb05583.x","volume":"27","author":"KN Buchi","year":"1987","unstructured":"Buchi KN, Rollins DE, Tolman KG, Achari R, Drissel D, Hulse JD. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol. 1987;27(11):880\u20134.","journal-title":"J Clin Pharmacol"},{"issue":"4 Suppl 3","key":"3585_CR206","first-page":"695","volume":"3","author":"LE Martin","year":"1976","unstructured":"Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976;3(4 Suppl 3):695\u2013710.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR207","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00007691-199206000-00006","volume":"14","author":"DR Luke","year":"1992","unstructured":"Luke DR, Awni WM, Halstenson CE, Opsahl JA, Matzke GR. Bioavailability of labetalol in patients with end-stage renal disease. Ther Drug Monit. 1992;14(3):203\u20138.","journal-title":"Ther Drug Monit"},{"issue":"Suppl 2","key":"3585_CR208","doi-asserted-by":"publisher","first-page":"157S","DOI":"10.1111\/j.1365-2125.1979.tb04773.x","volume":"8","author":"JJ McNeil","year":"1979","unstructured":"McNeil JJ, Anderson AE, Louis WJ, Morgan DJ. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol. 1979;8(Suppl 2):157S-S161.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3585_CR209","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00007691-198004000-00006","volume":"2","author":"J Kanto","year":"1980","unstructured":"Kanto J, Allonen H, Lehtonen A, Mantyla R, Pakkanen A. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol. Ther Drug Monit. 1980;2(2):145.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3585_CR210","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2125.1982.tb04936.x","volume":"14","author":"TK Daneshmend","year":"1982","unstructured":"Daneshmend TK, Roberts CJ. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol. 1982;14(1):73\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"3585_CR211","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0954-6820.1982.tb00410.x","volume":"665","author":"G Nyberg","year":"1982","unstructured":"Nyberg G, Hansson R, Tietz F. Single-dose pharmacokinetics of labetalol in healthy young men. Acta Med Scand Suppl. 1982;665:67\u201373.","journal-title":"Acta Med Scand Suppl"},{"issue":"8","key":"3585_CR212","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0002-9149(87)90385-7","volume":"60","author":"DR Abernethy","year":"1987","unstructured":"Abernethy DR, Schwartz JB, Plachetka JR, Todd EL, Egan JM. Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. Am J Cardiol. 1987;60(8):697\u2013702.","journal-title":"Am J Cardiol"},{"issue":"5","key":"3585_CR213","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2125.1984.tb02392.x","volume":"17","author":"HL Elliott","year":"1984","unstructured":"Elliott HL, Meredith PA, Sumner DJ, Reid JL. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. Br J Clin Pharmacol. 1984;17(5):573\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR214","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/clpt.1983.250","volume":"34","author":"KD Haegele","year":"1983","unstructured":"Haegele KD, Jaillon P, Cheymol G, Alken RG, Schechter PJ, Koch-Weser J. Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. Clin Pharmacol Ther. 1983;34(6):785\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR215","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/bdd.2510040402","volume":"4","author":"FJ Keeley","year":"1983","unstructured":"Keeley FJ, Weiner DL, Okerholm RA. Bioavailability of medroxalol in man. Biopharm Drug Dispos. 1983;4(4):305\u20139.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"3585_CR216","first-page":"169","volume":"18","author":"J Bonelli","year":"1980","unstructured":"Bonelli J, Hitzenberger G, Krause W, Wendt H, Speck U. Pharmacokinetics and pharmacodynamics of mepindolol sulphate. Int J Clin Pharmacol Ther Toxicol. 1980;18(4):169\u201376.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"1","key":"3585_CR217","first-page":"5","volume":"1","author":"AC Borchard","year":"1998","unstructured":"Borchard AC. Pharmacological properties of beta-adrenoceptor blocking drugs. J Clin Basic Cardiol. 1998;1(1):5\u20139.","journal-title":"J Clin Basic Cardiol"},{"issue":"1","key":"3585_CR218","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-2008-1069864","volume":"107","author":"C Seyfried","year":"1982","unstructured":"Seyfried C, Ledermann H, Rennekamp H, L\u2019Age M, Abshagen U. Pharmacokinetics of the beta-receptor blocker metipranolol in patients with liver cirrhosis (author\u2019s transl). Dtsch Med Wochenschr. 1982;107(1):21\u20136.","journal-title":"Dtsch Med Wochenschr"},{"issue":"4","key":"3585_CR219","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF00637616","volume":"21","author":"U Abshagen","year":"1982","unstructured":"Abshagen U, Betzien G, Kaufmann B, Endele G. Pharmacokinetics of metipranolol in normal man. Eur J Clin Pharmacol. 1982;21(4):293\u2013301.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3585_CR220","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00315024","volume":"38","author":"R Lapka","year":"1990","unstructured":"Lapka R, Sechser T, Rejholec V, Peterkova M, Votavova M. Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man. Eur J Clin Pharmacol. 1990;38(3):243\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3585_CR221","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF00266359","volume":"42","author":"I Janku","year":"1992","unstructured":"Janku I, Perlik F, Tkaczykova M, Brodanova M. Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects. Eur J Clin Pharmacol. 1992;42(3):337\u201340.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3585_CR222","first-page":"325","volume":"11","author":"C Appelgren","year":"1974","unstructured":"Appelgren C, Borg KO, Elofsson R, Johansson KA. Binding of adrenergic beta-receptor antagonists to human serum albumin. Acta Pharm Suec. 1974;11(4):325\u201332.","journal-title":"Acta Pharm Suec"},{"issue":"4","key":"3585_CR223","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF01061407","volume":"2","author":"CG Regardh","year":"1974","unstructured":"Regardh CG, Borg KO, Johansson R, Johnsson G, Palmer L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974;2(4):347\u201364.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"3585_CR224","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-198106050-00004","volume":"6","author":"CG Regardh","year":"1981","unstructured":"Regardh CG, Jordo L, Ervik M, Lundborg P, Olsson R, Ronn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6(5):375\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3585_CR225","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00613821","volume":"24","author":"CG Regardh","year":"1983","unstructured":"Regardh CG, Landahl S, Larsson M, Lundborg P, Steen B, Hoffmann KJ, et al. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol. 1983;24(2):221\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR226","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF03188836","volume":"19","author":"J Richard","year":"1994","unstructured":"Richard J, Cardot JM, Godbillon J. Inter- and intra-subject variability of metoprolol kinetics after intravenous administration. Eur J Drug Metab Pharmacokinet. 1994;19(2):157\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"3585_CR227","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00637630","volume":"33","author":"LJ Schaaf","year":"1987","unstructured":"Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, Perrier DG. Influence of smoking and gender on the disposition kinetics of metoprolol. Eur J Clin Pharmacol. 1987;33(4):355\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR228","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-198005020-00004","volume":"5","author":"L Jordo","year":"1980","unstructured":"Jordo L, Attman PO, Aurell M, Johansson L, Johnsson G, Regardh CG. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5(2):169\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 5","key":"3585_CR229","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0773.1975.tb03321.x","volume":"36","author":"CG Regardh","year":"1975","unstructured":"Regardh CG, Johnsson G, Jordo L, Solvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):45\u201358.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"6","key":"3585_CR230","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00005344-198011000-00002","volume":"2","author":"CG Regardh","year":"1980","unstructured":"Regardh CG, Johnsson G, Jordo L, Lungborg P, Persson BA, Ronn O. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol. 1980;2(6):715\u201323.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"3585_CR231","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.2042-7158.1984.tb04413.x","volume":"36","author":"L Patel","year":"1984","unstructured":"Patel L, Johnson A, Turner P. Nadolol binding to human serum proteins. J Pharm Pharmacol. 1984;36(6):414\u20135.","journal-title":"J Pharm Pharmacol"},{"issue":"5\u20136","key":"3585_CR232","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/j.1552-4604.1977.tb04609.x","volume":"17","author":"J Dreyfuss","year":"1977","unstructured":"Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Willard DA. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977;17(5\u20136):300\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"11\u201312","key":"3585_CR233","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/j.1552-4604.1979.tb01641.x","volume":"19","author":"J Dreyfuss","year":"1979","unstructured":"Dreyfuss J, Griffith DL, Singhvi SM, Shaw JM, Ross JJ Jr, Vukovich RA, et al. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol. 1979;19(11\u201312):712\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3585_CR234","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/BF00542499","volume":"33","author":"RA Morrison","year":"1988","unstructured":"Morrison RA, Singhvi SM, Creasey WA, Willard DA. Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects. Eur J Clin Pharmacol. 1988;33(6):625\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR235","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bcp.12917","volume":"82","author":"DV Neves","year":"2016","unstructured":"Neves DV, Lanchote VL, Moyses Neto M, Cardeal da Costa JA, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. Br J Clin Pharmacol. 2016;82(1):83\u201391.","journal-title":"Br J Clin Pharmacol"},{"issue":"3\u20134","key":"3585_CR236","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s002280050194","volume":"51","author":"A Himmelmann","year":"1996","unstructured":"Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol. 1996;51(3\u20134):259\u201364.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR237","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002280050237","volume":"51","author":"G Cheymol","year":"1997","unstructured":"Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 1997;51(6):493\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR238","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1046\/j.1365-2125.1997.54212.x","volume":"43","author":"F Kamali","year":"1997","unstructured":"Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3585_CR239","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0091270010370846","volume":"51","author":"C Lindamood","year":"2011","unstructured":"Lindamood C, Ortiz S, Shaw A, Rackley R, Gorski JC. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol. 2011;51(4):575\u201385.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3585_CR240","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jcpt.12180","volume":"39","author":"C Briciu","year":"2014","unstructured":"Briciu C, Neag M, Muntean D, Vlase L, Bocsan C, Buzoianu A, et al. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther. 2014;39(5):535\u201340.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3585_CR241","first-page":"208","volume":"88","author":"C Briciu","year":"2015","unstructured":"Briciu C, Neag M, Muntean D, Bocsan C, Buzoianu A, Antonescu O, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Med. 2015;88(2):208\u201313.","journal-title":"Clujul Med"},{"key":"3585_CR242","doi-asserted-by":"crossref","unstructured":"Riess W, Huerzeler H, Raschdorf F. The metabolites of oxprenolol (Trasicor) in man. Xenobiotica; the fate of foreign compounds in biological systems. 1974;4 (6):365\u201373.","DOI":"10.3109\/00498257409052112"},{"issue":"2","key":"3585_CR243","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF03188744","volume":"8","author":"P Dayer","year":"1983","unstructured":"Dayer P, Glasson P, Balant L, Striberni R, Fabre FJ. Differential consequences of renal failure on the pharmacokinetics of oxprenolol and its main metabolite. Eur J Drug Metab Pharmacokinet. 1983;8(2):181\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"3585_CR244","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2125.1985.tb05072.x","volume":"20","author":"JW Rigby","year":"1985","unstructured":"Rigby JW, Scott AK, Hawksworth GM, Petrie JC. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol. 1985;20(4):327\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3585_CR245","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0009-9236(95)90211-2","volume":"57","author":"ME Laethem","year":"1995","unstructured":"Laethem ME, Lefebvre RA, Belpaire FM, Vanhoe HL, Bogaert MG. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Clin Pharmacol Ther. 1995;57(4):419\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR246","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cpt1976204401","volume":"20","author":"WD Mason","year":"1976","unstructured":"Mason WD, Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther. 1976;20(4):401\u201312.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"3585_CR247","doi-asserted-by":"publisher","first-page":"163S","DOI":"10.1111\/j.1365-2125.1985.tb02757.x","volume":"19","author":"ID Bradbrook","year":"1985","unstructured":"Bradbrook ID, John VA, Morrison PJ, Rogers HJ, Spector RG. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. Br J Clin Pharmacol. 1985;19(Suppl 2):163S-S169.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR248","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2125.1979.tb00936.x","volume":"7","author":"CP Dawes","year":"1979","unstructured":"Dawes CP, Kendall MJ, Welling PG. Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals. Br J Clin Pharmacol. 1979;7(3):299\u2013302.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3585_CR249","doi-asserted-by":"publisher","first-page":"54D","DOI":"10.1016\/0002-9149(83)90643-4","volume":"52","author":"MJ Kendall","year":"1983","unstructured":"Kendall MJ. Pharmacokinetics of oxprenolol in the elderly. Am J Cardiol. 1983;52(9):54D-D56.","journal-title":"Am J Cardiol"},{"issue":"Suppl 2","key":"3585_CR250","doi-asserted-by":"publisher","first-page":"137S","DOI":"10.1111\/j.1365-2125.1985.tb02754.x","volume":"19","author":"KH Antonin","year":"1985","unstructured":"Antonin KH, Bieck P, Scheurlen M, Jedrychowski M, Malchow H. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Br J Clin Pharmacol. 1985;19(Suppl 2):137S-S142.","journal-title":"Br J Clin Pharmacol"},{"key":"3585_CR251","doi-asserted-by":"crossref","unstructured":"Dieterle W, Faigle JW, Kung W, Theobald W. The disposition and metabolism of 14C-oxprenolol.HCl in man. Xenobiotica; the fate of foreign compounds in biological systems. 1986;16 (2):181\u201391.","DOI":"10.3109\/00498258609043521"},{"issue":"2","key":"3585_CR252","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00315476","volume":"44","author":"R Koopmans","year":"1993","unstructured":"Koopmans R, Oosterhuis B, Karemaker JM, Wemer J, van Boxtel CJ. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man. Eur J Clin Pharmacol. 1993;44(2):171\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR253","first-page":"899","volume":"35","author":"R Gottschalk","year":"1985","unstructured":"Gottschalk R, Sistovaris N. Protein binding studies of furosemide and penbutolol. Arzneimittelforschung. 1985;35(6):899\u2013902.","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"3585_CR254","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF00686119","volume":"34","author":"C Aguirre","year":"1994","unstructured":"Aguirre C, Rodriguez-Sasiain JM, Calvo R. Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents. Cancer Chemother Pharmacol. 1994;34(1):86\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3585_CR255","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF00547425","volume":"29","author":"N Bernard","year":"1985","unstructured":"Bernard N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Pharmacokinetics of penbutolol and its metabolites in renal insufficiency. Eur J Clin Pharmacol. 1985;29(2):215\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR256","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2125.1977.tb00684.x","volume":"4","author":"JF Giudicelli","year":"1977","unstructured":"Giudicelli JF, Richer C, Chauvin M, Idrissi N, Berdeaux A. Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Br J Clin Pharmacol. 1977;4(2):135\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"5 Pt 1","key":"3585_CR257","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt1979255part1528","volume":"25","author":"FO Muller","year":"1979","unstructured":"Muller FO, Hundt HK, Bromley PA, Torres J, Vanderbeke O. Single and divided doses of penbutolol. Clin Pharmacol Ther. 1979;25(5 Pt 1):528\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"3585_CR258","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF01726915","volume":"64","author":"HR Ochs","year":"1986","unstructured":"Ochs HR, Hajdu P, Greenblatt DJ. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance. Klin Wochenschr. 1986;64(14):636\u201341.","journal-title":"Klin Wochenschr"},{"issue":"5","key":"3585_CR259","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00635892","volume":"29","author":"H Spahn","year":"1986","unstructured":"Spahn H, Kirch W, Hajdu P, Mutschler E, Ohnhaus EE. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine. Eur J Clin Pharmacol. 1986;29(5):555\u201360.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR260","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00637597","volume":"35","author":"D Brockmeier","year":"1988","unstructured":"Brockmeier D, Hajdu P, Henke W, Mutschler E, Palm D, Rupp W, et al. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding. Eur J Clin Pharmacol. 1988;35(6):613\u201323.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3585_CR261","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/BF00542123","volume":"25","author":"JA Vedin","year":"1983","unstructured":"Vedin JA, Wilhelmsson C, Maass L, Peterson LE. Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol. Eur J Clin Pharmacol. 1983;25(4):529\u201334.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3585_CR262","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jcpt.12310","volume":"40","author":"X Luo","year":"2015","unstructured":"Luo X, Lei Y, He L, Liu W, Li M, Ran L, et al. No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects. J Clin Pharm Ther. 2015;40(5):561\u20135.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"3585_CR263","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/ki.1979.86","volume":"15","author":"RL Galeazzi","year":"1979","unstructured":"Galeazzi RL, Gugger M, Weidmann P. beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney Int. 1979;15(6):661\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"3585_CR264","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00614385","volume":"7","author":"R Gugler","year":"1974","unstructured":"Gugler R, Herold W, Dengler HJ. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8\u20139","key":"3585_CR265","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/j.1552-4604.1977.tb05643.x","volume":"17","author":"D Lavene","year":"1977","unstructured":"Lavene D, Weiss YA, Safar ME, Loria Y, Agorus N, Georges D, et al. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol. 1977;17(8\u20139):501\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"3585_CR266","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/BF01037959","volume":"25","author":"FD Juma","year":"1983","unstructured":"Juma FD. Pharmacokinetics of pindolol in Kenyan Africans. Eur J Clin Pharmacol. 1983;25(3):425\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5 Pt 1","key":"3585_CR267","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/cpt1977225part1505","volume":"22","author":"NP Chau","year":"1977","unstructured":"Chau NP, Weiss YA, Safar ME, Lavene DE, Georges DR, Milliez PL. Pindolol availability in hypertensive patients with normal and impaired renal function. Clin Pharmacol Ther. 1977;22(5 Pt 1):505\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3585_CR268","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF01037948","volume":"25","author":"M Guerret","year":"1983","unstructured":"Guerret M, Cheymol G, Aubry JP, Cheymol A, Lavene D, Kiechel JR. Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur J Clin Pharmacol. 1983;25(3):357\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3585_CR269","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/clpt.1980.187","volume":"28","author":"WJ Stone","year":"1980","unstructured":"Stone WJ, Walle T. Massive propranolol metabolite retention during maintenance hemodialysis. Clin Pharmacol Ther. 1980;28(4):449\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3585_CR270","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cpt197314126","volume":"14","author":"G Bodem","year":"1973","unstructured":"Bodem G, Chidsey CA. Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther. 1973;14(1):26\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR271","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF00560339","volume":"7","author":"G Bodem","year":"1974","unstructured":"Bodem G, Grieser H, Eichelbaum M, Gugler R. Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol. 1974;7(4):249\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"3585_CR272","first-page":"83","volume":"12","author":"CM Kaye","year":"1975","unstructured":"Kaye CM, Kumana CR, Franklin DA, Baker LR. A study of practolol elimination in all grades of chronic renal failure. Int J Clin Pharmacol Biopharm. 1975;12(1\u20132):83\u20138.","journal-title":"Int J Clin Pharmacol Biopharm"},{"issue":"Suppl","key":"3585_CR273","first-page":"66P","volume":"26","author":"WJ Tilstone","year":"1974","unstructured":"Tilstone WJ, Semple PF, Boyle JA. Proceedings: The renal clearnace of practolol in man. J Pharm Pharmacol. 1974;26(Suppl):66P-P67.","journal-title":"J Pharm Pharmacol"},{"key":"3585_CR274","unstructured":"Giudicelli JF, Tillement JP, Boissier JR. Beta-adrenergic activity compared in vitro and in vivo and protein fixation. J Pharmacol. 1973:129\u201336."},{"issue":"2","key":"3585_CR275","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00607143","volume":"20","author":"C Graffner","year":"1981","unstructured":"Graffner C, Hoffmann KJ, Johnsson G, Lundborg P, Ronn O. Pharmacokinetic studies in man of the selective beta 1-adrenoceptor agonist, prenalterol. Eur J Clin Pharmacol. 1981;20(2):91\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"3585_CR276","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.0954-6820.1982.tb00838.x","volume":"659","author":"O Ronn","year":"1982","unstructured":"Ronn O. Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure. Acta Med Scand Suppl. 1982;659:89\u201398.","journal-title":"Acta Med Scand Suppl"},{"issue":"4","key":"3585_CR277","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/BF00609892","volume":"24","author":"U Dahlstrom","year":"1983","unstructured":"Dahlstrom U, Graffner C, Jonsson U, Hoffmann KJ, Karlsson E, Lagerstrom PO. Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure. Eur J Clin Pharmacol. 1983;24(4):495\u2013502.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3585_CR278","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/clpt.1983.245","volume":"34","author":"G Jennings","year":"1983","unstructured":"Jennings G, Bobik A, Oddie C, Hargreaves M, Korner P. Cardioselectivity of prenalterol and isoproterenol. Clin Pharmacol Ther. 1983;34(6):749\u201357.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR279","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF00544357","volume":"28","author":"EJ Sainsbury","year":"1985","unstructured":"Sainsbury EJ, Fitzpatrick D, Ikram H, Nicholls MG, Espiner EA, Ashley JJ. Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure. Eur J Clin Pharmacol. 1985;28(4):397\u2013403.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR280","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00563552","volume":"15","author":"O Ronn","year":"1979","unstructured":"Ronn O, Graffner C, Johnsson G, Jordo L, Lundborg P, Wikstrand J. Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. Eur J Clin Pharmacol. 1979;15(1):9\u201313.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR281","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00562614","volume":"17","author":"O Ronn","year":"1980","unstructured":"Ronn O, Fellenius E, Graffner C, Johnsson G, Lundborg P, Svensson L. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man. Eur J Clin Pharmacol. 1980;17(2):81\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"3585_CR282","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.0954-6820.1982.tb00839.x","volume":"659","author":"G Klein","year":"1982","unstructured":"Klein G, Wirtzfeld A, Bozler G, Ronn O, Graffner C. Compartment model of prenalterol. Acta Med Scand Suppl. 1982;659:99\u2013107.","journal-title":"Acta Med Scand Suppl"},{"issue":"4","key":"3585_CR283","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cpt1973144part1494","volume":"14","author":"GH Evans","year":"1973","unstructured":"Evans GH, Shand DG. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. Clin Pharmacol Ther. 1973;14(4):494\u2013500.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3585_CR284","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2125.1980.tb00511.x","volume":"10","author":"AJ Wood","year":"1980","unstructured":"Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG. Propranolol disposition in renal failure. Br J Clin Pharmacol. 1980;10(6):561\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR285","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/clpt.1984.107","volume":"35","author":"LS Olanoff","year":"1984","unstructured":"Olanoff LS, Walle T, Walle UK, Cowart TD, Gaffney TE. Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther. 1984;35(6):755\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3585_CR286","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/j.1552-4604.1987.tb05582.x","volume":"27","author":"G Cheymol","year":"1987","unstructured":"Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol. 1987;27(11):874\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"3585_CR287","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jps.2600760706","volume":"76","author":"RJ Straka","year":"1987","unstructured":"Straka RJ, Lalonde RL, Pieper JA, Bottorff MB, Mirvis DM. Nonlinear pharmacokinetics of unbound propranolol after oral administration. J Pharm Sci. 1987;76(7):521\u20134.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3585_CR288","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.1989.136","volume":"46","author":"T Walle","year":"1989","unstructured":"Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46(3):257\u201363.","journal-title":"Clin Pharmacol Ther"},{"key":"3585_CR289","doi-asserted-by":"crossref","unstructured":"Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol. 1996;42 (3):339\u201346.","DOI":"10.1046\/j.1365-2125.1996.03879.x"},{"issue":"1","key":"3585_CR290","first-page":"111","volume":"19","author":"DT Lowenthal","year":"1976","unstructured":"Lowenthal DT, Mutterperl R. The pharmacokinetics (PK) of multiple dose (MD) propranolol (P) in chronic renal disease (CRD). Clin Pharmacol Ther. 1976;19(1):111.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3585_CR291","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/clpt.1992.53","volume":"51","author":"JA Johnson","year":"1992","unstructured":"Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther. 1992;51(5):495\u2013500.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3585_CR292","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2125.1978.tb00862.x","volume":"6","author":"AJ Wood","year":"1978","unstructured":"Wood AJ, Carr K, Vestal RE, Belcher S, Wilkinson GR, Shand DG. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol. 1978;6(4):345\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR293","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/BF00563074","volume":"10","author":"YA Weiss","year":"1976","unstructured":"Weiss YA, Safar ME, Chevillard C, Frydman A, Simon A, Lemaire P, et al. Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension. Eur J Clin Pharmacol. 1976;10(6):387\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR294","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2125.1979.tb00896.x","volume":"7","author":"CM Castleden","year":"1979","unstructured":"Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol. 1979;7(1):49\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR295","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/clpt.1981.162","volume":"30","author":"GP Jackman","year":"1981","unstructured":"Jackman GP, McLean AJ, Jennings GL, Bobik A. No stereoselective first-pass hepatic extraction of propranolol. Clin Pharmacol Ther. 1981;30(3):291\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR296","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00005344-198503000-00029","volume":"7","author":"CP Venter","year":"1985","unstructured":"Venter CP, Joubert PH, Strydom WJ. Comparative pharmacokinetics of intravenous propranolol in black and white volunteers. J Cardiovasc Pharmacol. 1985;7(2):409\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"3585_CR297","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/BF00981142","volume":"31","author":"BG Arends","year":"1986","unstructured":"Arends BG, Bohm RO, van Kemenade JE, Rahn KH, van Baak MA. Influence of physical exercise on the pharmacokinetics of propranolol. Eur J Clin Pharmacol. 1986;31(3):375\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3585_CR298","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2125.1986.tb02837.x","volume":"21","author":"SL Bowman","year":"1986","unstructured":"Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol. 1986;21(5):529\u201332.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3585_CR299","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/bdd.2510070605","volume":"7","author":"E Cid","year":"1986","unstructured":"Cid E, Mella F, Lucchini L, Carcamo M, Monasterio J. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm Drug Dispos. 1986;7(6):559\u201366.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"3585_CR300","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/clpt.1982.223","volume":"32","author":"TW Wilson","year":"1982","unstructured":"Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB, et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther. 1982;32(6):676\u201385.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3585_CR301","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/01.CIR.52.2.313","volume":"52","author":"CA Chidsey","year":"1975","unstructured":"Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975;52(2):313\u20138.","journal-title":"Circulation"},{"issue":"4","key":"3585_CR302","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/clpt.1986.198","volume":"40","author":"LS Olanoff","year":"1986","unstructured":"Olanoff LS, Walle T, Cowart TD, Walle UK, Oexmann MJ, Conradi EC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther. 1986;40(4):408\u201314.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3585_CR303","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1600-0773.1976.tb03162.x","volume":"39","author":"M Anttila","year":"1976","unstructured":"Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh). 1976;39(1):118\u201328.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"6","key":"3585_CR304","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/BF00278585","volume":"38","author":"JM Poirier","year":"1990","unstructured":"Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d-sotalol and d, l-sotalol in healthy volunteers. Eur J Clin Pharmacol. 1990;38(6):579\u201382.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3585_CR305","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/j.1552-4604.1997.tb05627.x","volume":"37","author":"DE Salazar","year":"1997","unstructured":"Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 1997;37(9):799\u2013809.","journal-title":"J Clin Pharmacol"},{"issue":"8\u20139 Pt 2","key":"3585_CR306","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/j.1552-4604.1979.tb02522.x","volume":"19","author":"H Sundquist","year":"1979","unstructured":"Sundquist H, Anttila M, Simon A, Reich JW. Comparative bioavailability and pharmacokinetics of sotalol administered alone and in combination with hydrochlorothiazide. J Clin Pharmacol. 1979;19(8\u20139 Pt 2):557\u201364.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"3585_CR307","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.2042-7158.1994.tb03865.x","volume":"46","author":"T Uematsu","year":"1994","unstructured":"Uematsu T, Kanamaru M, Nakashima M. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. J Pharm Pharmacol. 1994;46(7):600\u20135.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3585_CR308","first-page":"68A","volume":"28","author":"AD Blair","year":"1980","unstructured":"Blair AD, Cutler RE, Lam FY. Pharmacokinetics of sotalol in humans with normal and varying degrees of renal function. Clin Res. 1980;28(1):68A.","journal-title":"Clin Res"},{"issue":"10","key":"3585_CR309","first-page":"486","volume":"27","author":"M Dumas","year":"1989","unstructured":"Dumas M, d\u2019Athis P, Besancenot JF, Chadoint-Noudeau V, Chalopin JM, Rifle G, et al. Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol. 1989;27(10):486\u20139.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"6","key":"3585_CR310","first-page":"442","volume":"7","author":"HK Sundquist","year":"1975","unstructured":"Sundquist HK, Anttila M, Forsstrom J, Kasanen A. Serum levels and half-life of sotalol in chronic renal failure. Ann Clin Res. 1975;7(6):442\u20136.","journal-title":"Ann Clin Res"},{"issue":"5","key":"3585_CR311","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/bdd.2510160505","volume":"16","author":"B Trausch","year":"1995","unstructured":"Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos. 1995;16(5):403\u201314.","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"3585_CR312","first-page":"392","volume":"19","author":"KO Haustein","year":"1981","unstructured":"Haustein KO, Fritzsche K. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent. Int J Clin Pharmacol Ther Toxicol. 1981;19(9):392\u20135.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"3585_CR313","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF00280137","volume":"42","author":"B Terhaag","year":"1992","unstructured":"Terhaag B, Palm U, Sahre H, Richter K, Oertel R. Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. Eur J Clin Pharmacol. 1992;42(4):461\u20132.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11\u201312","key":"3585_CR314","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/j.1552-4604.1978.tb01580.x","volume":"18","author":"T Ishizaki","year":"1978","unstructured":"Ishizaki T, Tawara K, Oyama Y, Nakaya H. Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. J Clin Pharmacol. 1978;18(11\u201312):511\u20138.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"3585_CR315","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF00716385","volume":"14","author":"OF Else","year":"1978","unstructured":"Else OF, Sorenson H, Edwards IR. Plasma timolol levels after oral and intravenous administration. Eur J Clin Pharmacol. 1978;14(6):431\u20134.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3585_CR316","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF01061376","volume":"23","author":"JA Vedin","year":"1982","unstructured":"Vedin JA, Kristianson JK, Wilhelmsson CE. Pharmacokinetics of intravenous timolol in patients with acute myocardial infarction and in healthy volunteers. Eur J Clin Pharmacol. 1982;23(1):43\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3585_CR317","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/bdd.2510020213","volume":"2","author":"R El-Rashidy","year":"1981","unstructured":"El-Rashidy R. Estimation of the systemic bioavailability of timolol in man. Biopharm Drug Dispos. 1981;2(2):197\u2013202.","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"3585_CR318","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2125.1975.tb00551.x","volume":"2","author":"JK Faulkner","year":"1975","unstructured":"Faulkner JK, Stopher DA, Walden R. Pharmacokinetic and pharmacological studies with tolamolol in man. Br J Clin Pharmacol. 1975;2(5):423\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3585_CR319","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF00609855","volume":"12","author":"PA Routledge","year":"1977","unstructured":"Routledge PA, Davies DM, Rawlins MD. Pharmacokinetics of tolamolol in the treatment of hypertension. Eur J Clin Pharmacol. 1977;12(3):171\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"3585_CR320","unstructured":"Balant L, Gorgia A, Marmy A, Tschopp JM. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)]. Nephrologie. 1980;1 (4):177\u201382."},{"issue":"6","key":"3585_CR321","first-page":"453","volume":"57","author":"HA Williams","year":"2019","unstructured":"Williams HA, Henke D, Elamin MEMO, Sandilands EA, Thomas SHL, Thompson JP, et al. Can poisons centre data inform safer prescribing? A pilot review of propranolol exposures reported to the UK National Poisons Information Service (NPIS). Clin Toxicol. 2019;57(6):453.","journal-title":"Clin Toxicol"},{"key":"3585_CR322","doi-asserted-by":"crossref","unstructured":"Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev. 2015;1:CD011447.","DOI":"10.1002\/14651858.CD011447"},{"key":"3585_CR323","doi-asserted-by":"crossref","unstructured":"Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. Cochrane Database Syst Rev. 2015;1:CD006962.","DOI":"10.1002\/14651858.CD006962.pub2"},{"issue":"13","key":"3585_CR324","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMoa1500964","volume":"373","author":"JJ Parienti","year":"2015","unstructured":"Parienti JJ, Mongardon N, Megarbane B, Mira JP, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"3585_CR325","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00134-019-05651-9","volume":"45","author":"HJ Shin","year":"2019","unstructured":"Shin HJ, Na HS, Koh WU, Ro YJ, Lee JM, Choi YJ, et al. Complications in internal jugular vs subclavian ultrasound-guided central venous catheterization: a comparative randomized trial. Intensive Care Med. 2019;45(7):968\u201376.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3585_CR326","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/aas.13214","volume":"63","author":"M Bjorkander","year":"2019","unstructured":"Bjorkander M, Bentzer P, Schott U, Broman ME, Kander T. Mechanical complications of central venous catheter insertions: A retrospective multicenter study of incidence and risks. Acta Anaesthesiol Scand. 2019;63(1):61\u20138.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"3585_CR327","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2013.07.009","volume":"63","author":"B Wong","year":"2014","unstructured":"Wong B, Zimmerman D, Reintjes F, Courtney M, Klarenbach S, Dowling G, et al. Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective. Am J Kidney Dis. 2014;63(2):251\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3585_CR328","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.ajkd.2014.08.013","volume":"65","author":"KK Tennankore","year":"2015","unstructured":"Tennankore KK, d\u2019Gama C, Faratro R, Fung S, Wong E, Chan CT. Adverse technical events in home hemodialysis. Am J Kidney Dis. 2015;65(1):116\u201321.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3585_CR329","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","volume":"23","author":"MH Mokrzycki","year":"1994","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817\u201327.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3585_CR330","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1537-2995.1989.29289146829.x","volume":"29","author":"DM Sutton","year":"1989","unstructured":"Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. 1989;29(2):124\u20137.","journal-title":"Transfusion"},{"issue":"6","key":"3585_CR331","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ajem.2017.10.048","volume":"36","author":"X Yang","year":"2018","unstructured":"Yang X, Xin S, Zhang Y, Li T. Early hemoperfusion for emergency treatment of carbamazepine poisoning. Am J Emerg Med. 2018;36(6):926\u201330.","journal-title":"Am J Emerg Med"},{"issue":"7","key":"3585_CR332","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1553-2712.1997.tb03758.x","volume":"4","author":"MW Shannon","year":"1997","unstructured":"Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med. 1997;4(7):674\u20138.","journal-title":"Acad Emerg Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-021-03585-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T15:19:23Z","timestamp":1725203963000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-021-03585-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":332,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3585"],"URL":"https:\/\/doi.org\/10.1186\/s13054-021-03585-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TDN reports personal fees from MediBeacon, CytoSorbents, and McGraw-Hill Education outside the submitted work. MG is a scholar of the Fonds de Recherche du Qu\u00e9bec\u2014Sant\u00e9. DMR acknowledges support of St. Vincent\u2019s Centre for Applied Medical Research Clinician \u201cBuy-Out\u201d Program. AV reports consulting functions for NxStage, Astute Medical, and Boehringer-Ingelheim and speaker fees from Sanofi-Aventis. MO has received speaker honoraria and research funding from Fresenius Medical and Baxter and has had consulting functions for Nxstage and Baxter. All remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}